![PDF) Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4 PDF) Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4](https://www.researchgate.net/publication/282568515/figure/fig2/AS:289326169640975@1445992142934/DOX-washout-of-shRNA-knockdown-of-IKZF1-or-IKZF3-but-not-c-MYC-or-IRF4-leads-to-a-partial_Q320.jpg)
PDF) Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4
![PDF) Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4 PDF) Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4](https://www.researchgate.net/publication/282568515/figure/fig4/AS:293081439064068@1446887469220/RNA-mediated-knockdown-of-IKZF1-or-IKZF3-inhibits-proliferation-and-induces-apoptosis-in_Q320.jpg)
PDF) Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4
![PDF) Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4 PDF) Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4](https://www.researchgate.net/publication/282568515/figure/fig7/AS:293081447452688@1446887470547/RNA-mediated-knockdown-of-IKZF1-or-IKZF3-leads-to-the-downregulation-of-c-Myc-and-IRF4_Q320.jpg)
PDF) Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4
![PDF) Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4 PDF) Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4](https://www.researchgate.net/publication/282568515/figure/fig6/AS:293081447452679@1446887470357/Ikaros-Aiolos-c-Myc-and-IRF4-are-upregulated-simultaneously-in-primary-MM-samples_Q320.jpg)